NO20004413L - HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en metode til å påvise antistoffer indusert av HIV - Google Patents

HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en metode til å påvise antistoffer indusert av HIV

Info

Publication number
NO20004413L
NO20004413L NO20004413A NO20004413A NO20004413L NO 20004413 L NO20004413 L NO 20004413L NO 20004413 A NO20004413 A NO 20004413A NO 20004413 A NO20004413 A NO 20004413A NO 20004413 L NO20004413 L NO 20004413L
Authority
NO
Norway
Prior art keywords
hiv
antigens
vaccine composition
test kits
antibodies induced
Prior art date
Application number
NO20004413A
Other languages
English (en)
Other versions
NO20004413D0 (no
NO314588B1 (no
Inventor
Birger Soerensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Priority to NO20004413A priority Critical patent/NO314588B1/no
Publication of NO20004413D0 publication Critical patent/NO20004413D0/no
Priority to HK04102846.8A priority patent/HK1059940B/xx
Priority to AU2001282706A priority patent/AU2001282706B2/en
Priority to AU8270601A priority patent/AU8270601A/xx
Priority to PCT/NO2001/000362 priority patent/WO2002020554A2/en
Priority to EP07014954A priority patent/EP1878742A3/en
Priority to CNB018157424A priority patent/CN1282656C/zh
Priority to NZ524556A priority patent/NZ524556A/en
Priority to BR0114036-1A priority patent/BR0114036A/pt
Priority to DE60135564T priority patent/DE60135564D1/de
Priority to EP01961444A priority patent/EP1322665B1/en
Priority to ES01961444T priority patent/ES2312465T3/es
Priority to SK402-2003A priority patent/SK287917B6/sk
Priority to NZ535148A priority patent/NZ535148A/en
Priority to US10/129,331 priority patent/US7009037B2/en
Priority to JP2002525174A priority patent/JP2004508381A/ja
Priority to EA200300336A priority patent/EA006308B1/ru
Priority to HU0303134A priority patent/HUP0303134A3/hu
Priority to CA002421193A priority patent/CA2421193A1/en
Priority to ZA200301740A priority patent/ZA200301740B/en
Priority to CNA2006101517487A priority patent/CN101104636A/zh
Priority to AT01961444T priority patent/ATE406380T1/de
Priority to ARP010104196A priority patent/AR033998A1/es
Priority to MYPI20014139A priority patent/MY136081A/en
Publication of NO20004413L publication Critical patent/NO20004413L/no
Publication of NO314588B1 publication Critical patent/NO314588B1/no
Priority to US11/211,576 priority patent/US7612168B2/en
Priority to AU2007202739A priority patent/AU2007202739B2/en
Priority to ARP080105262A priority patent/AR071262A2/es
Priority to JP2011128389A priority patent/JP2011219481A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Extraction Or Liquid Replacement (AREA)
NO20004413A 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV NO314588B1 (no)

Priority Applications (28)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
AT01961444T ATE406380T1 (de) 2000-09-04 2001-09-03 Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
US10/129,331 US7009037B2 (en) 2000-09-04 2001-09-03 Modified HIV-1gag p17 peptide and immunogenic composition
JP2002525174A JP2004508381A (ja) 2000-09-04 2001-09-03 Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
AU8270601A AU8270601A (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
PCT/NO2001/000362 WO2002020554A2 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
EP07014954A EP1878742A3 (en) 2000-09-04 2001-09-03 HIV peptides, antigens, vaccine compositions, immunoassay and a method of detecting antibodies induced by HIV
CNB018157424A CN1282656C (zh) 2000-09-04 2001-09-03 来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
NZ524556A NZ524556A (en) 2000-09-04 2001-09-03 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
BR0114036-1A BR0114036A (pt) 2000-09-04 2001-09-03 Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
DE60135564T DE60135564D1 (de) 2000-09-04 2001-09-03 Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
EP01961444A EP1322665B1 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and their applications, such as vaccines
ES01961444T ES2312465T3 (es) 2000-09-04 2001-09-03 Peptidos de vih de regiones conservadas en gag p17 y sus aplicaciones, tales como vacunas.
SK402-2003A SK287917B6 (sk) 2000-09-04 2001-09-03 Peptide derived from HIV-1gag p17, antigen comprising the peptide and use thereof, vaccine composition, antibody, nucleic acid, expression vector and host cell
NZ535148A NZ535148A (en) 2000-09-04 2001-09-03 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
HK04102846.8A HK1059940B (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
HU0303134A HUP0303134A3 (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
CNA2006101517487A CN101104636A (zh) 2000-09-04 2001-09-03 来自gag p17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
EA200300336A EA006308B1 (ru) 2000-09-04 2001-09-03 Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
CA002421193A CA2421193A1 (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions,immunoassay kit and a method of detecting antibodies induced by hiv
ZA200301740A ZA200301740B (en) 2000-09-04 2001-09-03 HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines.
AU2001282706A AU2001282706B2 (en) 2000-09-04 2001-09-03 HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
MYPI20014139A MY136081A (en) 2000-09-04 2001-09-04 Modified hiv - 1gag p17 peptide and immunogenic composition
ARP010104196A AR033998A1 (es) 2000-09-04 2001-09-04 Peptidos de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
US11/211,576 US7612168B2 (en) 2000-09-04 2005-08-26 Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AU2007202739A AU2007202739B2 (en) 2000-09-04 2007-06-13 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ARP080105262A AR071262A2 (es) 2000-09-04 2008-12-03 Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
JP2011128389A JP2011219481A (ja) 2000-09-04 2011-06-08 Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Publications (3)

Publication Number Publication Date
NO20004413D0 NO20004413D0 (no) 2000-09-04
NO20004413L true NO20004413L (no) 2002-03-05
NO314588B1 NO314588B1 (no) 2003-04-14

Family

ID=19911533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Country Status (19)

Country Link
US (2) US7009037B2 (no)
EP (2) EP1878742A3 (no)
JP (2) JP2004508381A (no)
CN (2) CN101104636A (no)
AR (2) AR033998A1 (no)
AT (1) ATE406380T1 (no)
AU (3) AU2001282706B2 (no)
BR (1) BR0114036A (no)
CA (1) CA2421193A1 (no)
DE (1) DE60135564D1 (no)
EA (1) EA006308B1 (no)
ES (1) ES2312465T3 (no)
HU (1) HUP0303134A3 (no)
MY (1) MY136081A (no)
NO (1) NO314588B1 (no)
NZ (2) NZ524556A (no)
SK (1) SK287917B6 (no)
WO (1) WO2002020554A2 (no)
ZA (1) ZA200301740B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503205A (ja) 2000-02-04 2004-02-05 デューク・ユニバーシティー ヒト免疫不全ウイルスワクチン
CA2619709C (en) * 2005-08-26 2012-05-01 Novo Nordisk A/S A method of modifying a macromolecular system
ATE425204T1 (de) * 2005-08-26 2009-03-15 Novo Nordisk As Verfahren zur modifizierung eines makromolekularen systems
FI120376B (fi) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Menetelmä fuusiopolypeptidin valmistamiseksi
US8431153B2 (en) 2008-09-09 2013-04-30 Celebrity Biogens, Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
JP6294076B2 (ja) * 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
IN2014KN02769A (no) * 2012-06-06 2015-05-08 Bionor Immuno As
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT
AU2017292582C1 (en) * 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
JP2020524996A (ja) 2017-06-16 2020-08-27 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
RU2727673C1 (ru) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Антитела против белка р17 ВИЧ-1 субтипа А
GB2610556A (en) * 2021-09-02 2023-03-15 113 Botanicals Ltd Extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) * 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) * 1991-06-13 1991-06-13 Replico Medical Ab Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
US6525173B1 (en) 1997-01-02 2003-02-25 Universidade Federal De Minas Gerais Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
GB9703802D0 (en) * 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
US5972339A (en) * 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Also Published As

Publication number Publication date
HK1059940A1 (en) 2004-07-23
EP1878742A2 (en) 2008-01-16
NZ524556A (en) 2005-01-28
HUP0303134A2 (hu) 2005-03-29
ZA200301740B (en) 2004-06-21
NO20004413D0 (no) 2000-09-04
EA200300336A1 (ru) 2003-08-28
CN101104636A (zh) 2008-01-16
AU2001282706B2 (en) 2007-03-22
NO314588B1 (no) 2003-04-14
EP1878742A3 (en) 2008-04-30
AU8270601A (en) 2002-03-22
AR071262A2 (es) 2010-06-09
AU2007202739A1 (en) 2007-07-05
CN1460111A (zh) 2003-12-03
AU2007202739B2 (en) 2009-12-03
ES2312465T3 (es) 2009-03-01
AR033998A1 (es) 2004-01-21
EP1322665A2 (en) 2003-07-02
WO2002020554A3 (en) 2002-06-13
JP2004508381A (ja) 2004-03-18
DE60135564D1 (de) 2008-10-09
US20040115615A1 (en) 2004-06-17
SK4022003A3 (en) 2003-09-11
US7612168B2 (en) 2009-11-03
EP1322665B1 (en) 2008-08-27
JP2011219481A (ja) 2011-11-04
CA2421193A1 (en) 2002-03-14
WO2002020554A2 (en) 2002-03-14
MY136081A (en) 2008-08-29
ATE406380T1 (de) 2008-09-15
NZ535148A (en) 2007-06-29
US7009037B2 (en) 2006-03-07
BR0114036A (pt) 2003-07-22
US20070237783A1 (en) 2007-10-11
CN1282656C (zh) 2006-11-01
SK287917B6 (sk) 2012-03-02
HUP0303134A3 (en) 2012-09-28
EA006308B1 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
NO20004413L (no) HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en metode til å påvise antistoffer indusert av HIV
WO2001096875A3 (en) Hcv antigen/antibody combination assay
MXPA01012662A (es) Deteccion temprana de flavivirus que utiliza la glicoproteina ns1.
DK1504266T3 (da) Fremgangsmåde til samtidig detektering af en infekteret mikroorganismes antigen og antistof
NO20004412L (no) HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisningav antistoffer fremkalt av HIV
DK1232392T3 (da) Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
EP1227159A4 (en) MONOCLONAL ANTIBODY, HYBRIDOMA, IMMUNITY TEST AND DIAGNOSTIC KIT
DE60219124D1 (de) Verfahren und Kit zum Nachweis, oder zum Quantifizieren von, Metaboliten von Fentanyl und Metaboliten von Fentanyl Analoga
BR0314166A (pt) Teste de hcv
WO2002072606A3 (en) Epitope testing using hla
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
EP1347298A3 (en) Immunoassay method, test strip for use therein, and immunoassay apparatus
WO2006108033A3 (en) Recombinant antigens for the detection of coxiella burnetii
DK1257823T3 (da) Fremgangsmåde til påvisning af Helicobacter pylori og heilmanii
KR930700548A (ko) 자궁내막 항체 측정방법 및 측정용 자궁내막 항원, 조성물, 테스트킷
WO2001051926A3 (en) Competitive enzyme immunoassay for assessing total antigen content of aluminum-adsorbed antigens
MY137138A (en) Diagnostic reagents and preparing methods thereof
DE60138981D1 (de) Immunoassay für H. pylori in Fäkalienproben mit Hilfe von gattungsspezifischen Antikörpern
AU2004200155B2 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ATE389179T1 (de) Verfahren und kit zum nachweis von antigenen
WO2006113522A3 (en) Methods of detecting hepatitis c virus
WO2001044299A3 (de) Antikörper und verfahren zu ihrer herstellung, deren verwendung, sowie immunisierungscocktails, immunoassay-sets und peptide
WO1998019703A3 (de) Pharmazeutische antigen-/antikörperpräparation
BR0204612A (pt) Anticorpos monoclonais antinúcleo de hcv

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees